| IV iron use, by DOPPS country and cross-section |
| N Ptnts | Wgtd % | Total N | ||
|---|---|---|---|---|
| DOPPS Country | DOPPS Cross-section | 5,584 | 61.2% | 9,117 |
| All | DOPPS 2(2002) | |||
| DOPPS 3(2006) | 5,823 | 68.0% | 8,552 | |
| DOPPS 3(2007) | 5,215 | 68.0% | 7,672 | |
| AusNZ | DOPPS 2(2002) | 329 | 64.0% | 513 |
| DOPPS 3(2006) | 402 | 76.2% | 527 | |
| DOPPS 3(2007) | 351 | 72.2% | 486 | |
| Belgium | DOPPS 2(2002) | 473 | 87.8% | 538 |
| DOPPS 3(2006) | 438 | 85.7% | 509 | |
| DOPPS 3(2007) | 340 | 78.9% | 420 | |
| Canada | DOPPS 2(2002) | 390 | 65.4% | 601 |
| DOPPS 3(2006) | 355 | 64.4% | 551 | |
| DOPPS 3(2007) | 320 | 71.5% | 445 | |
| France | DOPPS 2(2002) | 331 | 62.9% | 528 |
| DOPPS 3(2006) | 394 | 71.8% | 551 | |
| DOPPS 3(2007) | 420 | 76.3% | 543 | |
| Germany | DOPPS 2(2002) | 433 | 75.7% | 571 |
| DOPPS 3(2006) | 462 | 79.0% | 583 | |
| DOPPS 3(2007) | 471 | 75.1% | 623 | |
| Italy | DOPPS 2(2002) | 296 | 51.3% | 576 |
| DOPPS 3(2006) | 337 | 63.1% | 533 | |
| DOPPS 3(2007) | 344 | 63.3% | 542 | |
| Japan | DOPPS 2(2002) | 643 | 35.5% | 1,805 |
| DOPPS 3(2006) | 671 | 36.7% | 1,832 | |
| DOPPS 3(2007) | 819 | 43.8% | 1,867 | |
| Spain | DOPPS 2(2002) | 475 | 77.4% | 613 |
| DOPPS 3(2006) | 518 | 77.9% | 666 | |
| DOPPS 3(2007) | 441 | 78.2% | 555 | |
| Sweden | DOPPS 2(2002) | 436 | 79.8% | 547 |
| DOPPS 3(2006) | 460 | 85.2% | 542 | |
| DOPPS 3(2007) | 420 | 81.8% | 511 | |
| UK | DOPPS 2(2002) | 415 | 73.2% | 565 |
| DOPPS 3(2006) | 342 | 77.1% | 445 | |
| DOPPS 3(2007) | 288 | 83.2% | 351 | |
| US | DOPPS 2(2002) | 1,363 | 60.1% | 2,260 |
| DOPPS 3(2006) | 1,444 | 79.0% | 1,813 | |
| DOPPS 3(2007) | 1,001 | 75.9% | 1,329 | |
| Medications reported as prescribed in previous four months, among all patients |
Please see additional methodological information in the Data Sources and Methods section.